As compared to the OAM cohort, Table 1 shows the SGLT2i group had a lower prevalence of MI, angina, and warfarin usage, but had a higher prevalence of using metformin, sulfonylureas, thiazolidinediones (TZD), dipeptidyl peptidase 4 inhibitors (DPP4i), and glucagon-like peptide 1 agonists (GLP1a). This evidence concerns the gene GCG and angina pectoris.